Different Ways to Die: Cell Death Pathways and Their Association With Spinal Cord Injury

Article information

Neurospine. 2023;20(2):430-448

Publication date (electronic) : 2023 March 2

doi : https://doi.org/10.14245/ns.2244976.488

Lahanya Guha ¹

, Nidhi Singh ²

, Hemant Kumar^,¹

¹Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Ahmedabad, Gandhinagar, Gujarat, India

²Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER)- Ahmedabad, Gandhinagar, Gujarat, India

Corresponding Author Hemant Kumar Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research Ahmedabad, Opposite Air force Station, Palaj, Gandhinagar, Gujarat 382355, India Email: hemantbhave@gmail.com; hemant@niperahm.ac.in

Received 2022 November 17; Revised 2023 February 7; Accepted 2023 February 10.

Abstract

Cell death is a systematic/nonsystematic process of cessation of normal morphology and functional properties of the cell to replace and recycle old cells with new also promoting inflammation in some cases. It is a complicated process comprising multiple pathways. Some are well-explored, and others have just begun to be. The research on appropriate control of cell death pathways after acute and chronic damage of neuronal cells is being widely researched today due to the lack of regeneration and recovering potential of a neuronal cell after sustaining damage and the inability to control the direction of neuronal growth. In the progression and onset of various neurological diseases, impairments in programmed cell death signaling processes, like necroptosis, apoptosis, ferroptosis, pyroptosis, and pathways directly or indirectly linked, like autophagy as in nonprogrammed necrosis, are observed. Spinal cord injury (SCI) involves the temporary or permanent disruption of motor activities due to the death of a neuronal and glial cell in the spinal cord accompanied by axonal degeneration. Recent years have seen a significant increase in research on the intricate biochemical interactions that occur after a SCI. Different cell death pathways may significantly impact the subsequent damage processes that lead to the eventual neurological deficiency after an injury to the spinal cord. A better knowledge of the molecular basis of the involved cell death pathways might help enhance neuronal and glial survival and neurological deficits, promoting a curative path for SCI.

Keywords: Cell death pathways; Programmed cell death; Nonprogrammed cell death; Spinal cord injury

INTRODUCTION

Spinal cord injury (SCI) is the traumatic or nontraumatic damage to the spinal cord, causing impairment of motor function and leading to morbidity or permanent paralysis [1]. In today’s world, SCI is still a significant source of illness and mortality. Acute traumatic SCI affects people worldwide, with an annual incidence of 15–40 cases per million [2]. SCI is particularly concerning on a social level because it primarily affects young, otherwise healthy people, with injuries happening most frequently in those between the ages of 15 and 25 [3]. Creating effective recovery treatments requires a thorough understanding of SCI pathophysiology, stages, and diverse wound recovery mechanisms [4]. The major reason of SCI progression is the death of these different types cells relevant to spinal cord structural and functional homeostasis, initiated by numerous crosstalk between different cell death pathways. Many cell types interact in normal spinal cord physiology, including astrocytes, neurons, microglia, and oligodendrocytes. These multicellular interactions are disrupted and disorganized after an SCI, resulting in slowed spinal healing [5]. The critical process of neuroinflammation, which is connected to SCI, is implicated in neutrophils, microglia, macrophages, astrocytes, dendritic cells (DCs), B- and T-lymphocytes, as well as molecules including cytokines and prostanoids [6]. It involves the death of spinal cord neurons and associating glial cells like astrocytes, oligodendrocytes, and microglias [7]. Neuronal and glial cell death ultimately catalyzes axonal degeneration, accelerating SCI progression. Apoptosis, autophagy, and necrosis are well established in SCI. They are welldocumented in helping axonal degeneration also [8]. New cell death pathways include common ones like ferroptosis, mitoptosis, parthanatos, and pyroptosis, and rare ones like oxieptosis, alkaliptosis, and autoschizis, are being discovered in the pathogenesis and progression of SCI [9].

Due to their activation, SCI inevitably results in functional decline. The severity of subsequent damage caused by a cascade of cellular and molecular processes initiated by the primary trauma determines the fate of SCI [10]. After a human SCI, the necrotic and apoptotic cell death processes are known to occur. The contribution of autophagy in SCI is also well established [11]. The spinal cord's diameter is relatively small, and even a tiny transverse expansion of initial damage would result in a more significant disconnection between the brain and the spinal cord below the lesion site. Therefore, developing strategies to limit the secondary degenerative processes would be of utmost importance in SCI research. This review aims to summarize all programmed and non-programmed cell death (non-PCD) pathways along with their molecular mechanisms, crosstalks and Involvement in the progression of the pathophysiology of SCI to pave the way for developing effective treatment strategies.

CELL DEATH PATHWAYS AND THEIR RELEVANCE IN THE PROGRESSION OF SCI

Cell death is the biochemical process by which a cell loses its ability to maintain its cellular morphology and homeostasis and serve its functions. It can be programmed when a cell becomes too old to continue serving its normal function or can be nonprogrammed, spontaneously induced by specific mechanical, ischemic or chemical trauma, causing the cell to die spontaneously. On one side, cell death is essential for a cell to cease its morphological and functional features through complicated programmed or nonprogrammed interactions, leading to organismic homeostasis. On the other hand, it can be detrimental as it can promote inflammation at the death site and affect other healthy cells to die, making it a double-edged sword [12]. The hallmarks of multiple cell death modes are identified and fitted into a basic classification framework, where cell death entities are classed as programmed or non-PCD, depending on their signal dependency. PCD is categorized into 2 types: apoptotic and nonapoptotic cell death. Programmed apoptotic cell death causes apoptosis and anoikis showing membrane blebbing, mitochondrial disruption, and cell detachment from the surface. Programmed nonapoptotic cell death includes vacuolepresenting cell death (autophagy, entosis, methuosis, and paraptosis), mitochondria-dependent cell death (mitoptosis and parthanatos), iron-dependent cell death (ferroptosis), and immunomodulatory cell death (pyroptosis and NETosis). Non-PCD includes necrosis which is vital in injury progression. Cell death is vital in disease development, notably cancer and injuries [13,14]. All cell death pathways show a plethora of morphological changes like the formation of fluid-filled bubbles inside the cell (paraptosis), mitochondrial disruption (mitoptosis and parthanatos), accumulation of iron (ferroptosis), formation of extracellular traps and gasdermin D mediated cleavage formation (NETosis and pyroptosis) or spontaneously induced (necrosis). Understanding cell death is vital for understanding how some illnesses progress, which leads to new treatment development (Figs. 1, 2).

Fig. 1.

Classification, mechanism, and factors involved in different key cell death pathways. Key cell death pathways can be broadly classified on the basis of showing systemic death phenomenon or the presence of apoptotic hallmarks. (A) The first one is programmed apoptotic death consisting of caspase-mediated apoptosis and anoikis. (B) There are also nonprogrammed nonapoptotic cell death pathways like necrosome-mediated necrosis. (C) The majority of cell death pathways are programmed nonapoptotic origin, including vacuole-mediated autophagy and paraptosis, mitochondria-mediated mitoptosis and parthanatos, immune-factor-mediated NETosis and pyroptosis and miscellaneous factor-mediated necroptosis. DNA, Deoxyribonucleic acid; ULK1, Unc-51-like kinase 1; ATP, adenosine triphosphate; PARP-1, poly-(ADP-ribose)-polymerase 1; NETs, neutrophil extracellular traps; GSDMD, gasdermin D; MLK-1, mixed lineage kinase 1; RIPK, receptor-interacting protein kinase.

Fig. 2.

Morphology of different key cell death pathways. (A) Apoptosis and anoikis are classified under apoptotic programmed cell death (PCD). In apoptosis, nuclear DNA is fragmented, and the membrane is blebbed, while in anoikis, the cells lose their anchorage property to metastasize to other tissues. The morphological alteration in apoptotic non-PCDs is based on the presence of vacuoles, disruption of membrane integrity, organelle arrangement, chromatin density, and cell size. (B) It can involve mitochondria-mediated (mitoptosis, parthanatos), where mitochondrial integrity is disrupted, disabling the cell from producing energy for its survival; vacuole-mediated (autophagy, paraptosis), where the cell develops large hollow or fluid-filled vacuoles or cracks, iron-mediated (Ferroptosis), where cell accumulates iron inside to produce toxic effects, Immune factor-mediated (NETosis, pyroptosis) where immunological cascade controls the death of the cell or other various factor-mediated (necroptosis) that involves the change in oxidative stress, pH and formation of a necrotic cavity. (C) Nonprogrammed nonapoptotic form of cell death contains necrosis involving the spontaneous formation of necrosome and the release of cellular material that attack neighboring cells to go into necrosis. Triggered by toxins, physical injuries, and infections disrupting ionic pumps leading to Ca2+ influx, resulting in morphological alterations such as cytoplasmic swelling, consequential intracellular organelle loss with little to no chromatin condensation, and plasma membrane rupture.

Cell death pathways play a major role in SCI pathogenesis and progression. Initial tissue injury results in secondary injury, which further damages the spinal tissues chemically and mechanically, causes neuronal excitotoxicity because the calcium level in the cells is too high, and increases reactive oxygen and glutamate levels [15]. These events result in brain/spinal cord dysfunction by harming the underlying proteins, phospholipids, and nucleic acids [16]. The secondary injury phase, which follows the main damage phase and lasts several weeks, reflects multifeatured pathological processes. Caspase-mediated cell signaling, ischemia, vasculopathy, hydrops, excitotoxicity, ionic imbalance, inflammation, lipid peroxidation, free radical generation, demyelination, Wallerian degeneration, microglial scarring, and cyst formation are all clinical manifestations of secondary injury [16]. Ischemia is one of the major factors in disease progression, which can develop very once after traumatic SCI, and if it goes untreated, further damage may start within the first 3 hours and last for at least 24 hours [17]. In addition, monocytes, neutrophils, T and B lymphocyte cells, and macrophage infiltration occur due to blood vessel breakage, which causes bleeding in the spinal tissues. This phenomenon is also associated with the release of inflammatory cytokines such as interleukin (IL)-1α, IL-1β, IL-6, and tumor necrosis factor (TNF) after 6 to 12 hours following damage [18]. Inflammation of neurons is promoted by immune cell penetration and inflammatory cytokines [18]. Secondary injuries come in 3 forms: acute, subacute, and chronic, followed by primary injury [19].

Further, multiple inflammatory mediators, such as leukotrienes, bradykinin, prostaglandins, platelet-activating factors, and serotonin, are present in higher concentrations in the injured area [20]. Cell death is the cell’s final event, which can be segregated into 2 forms; apoptosis and necrosis. Apoptosis is the PCD pathway; nowadays, many PCDs are discovered [21]. PCD is crucial for getting rid of unwanted and damaged cells and can serve as a defense; it is also linked with CNS disorders and SCI [22]. On the other hand, apoptosis is a known physiological process that usually occurs and may be crucial in secondary SCI. The secondary injury after SCI is thought to be caused by the continuation of cellular destruction through apoptosis, and the longterm neurological deficits after SCI may result from a wide range of apoptosis of neurons and oligodendrocytes in the injured spinal cord [23].

DIFFERENT CELL DEATH PATHWAYS ASSOCIATED WITH SCI

SCI pathophysiology is characterized by blood-spinal cord barrier collapse and breakdown, transmigration of immune cells, rupture of cellular axons and membranes, and myelin disintegration [6]. Some key signaling pathways, including CDK1/E2F1, AMPK/SIRT1, JNK/c-JUN, and Wnt-β catenin signaling pathways, are already involved in regulating apoptotic activity in SCI [24]. Recently, programmed and non-PCD has been recognized as a significant process after SCI. Several kinds of cell death pathways, including apoptosis, autophagy, ferroptosis, paraptosis, netosis, pyroptosis, and necroptosis, have been found in the direct link in the progression of primary and secondary SCI [9]. Here we will discuss them in more depth and detail (Fig. 3).

Fig. 3.

Essential pathways involved in cell death associated with spinal cord injury. This image illustrates different cell death pathways and their crosstalks (apoptosis, anoikis, autophagy, methuosis, entosis, paraptosis, parthanatos, mitoptosis, ferroptosis, NETosis, pyroptosis, necroptosis, oxieptosis, and alkaliptosis). Anoikis uses the same signaling pathways as apoptosis involving the membrane and mitochondrial disruption and activation on executioner caspase-3, except that poor or incorrect cell-matrix connections trigger it. This caspase 3 can also trigger mitochondrial rupture causing mitoptosis and PARP1 activation causing AIF and MIF to dimerize and translocate to trigger parthanatos. Autophagy basically involve ULK1 mediated autophagosome formation that one side can trigger cleaning of cellular debries at injury site and also promote inflammation by triggering cytokine production. Ferroptosis involves GPX4 activation by iron accumulation leading to pH change and ROS production possibly triggering oxieptosis and alkaliptosis. Necoptosis occours by MLCK phosphorylation induced necrosome formation. Cell death modes with unknown mechanisms were excluded. The arrow direction shows the causal relationship. TRADD, type 1-associated death domain protein; FADD, Fas-associated death domain protein; RIPK, receptor-interacting protein kinase; MLKL, mixed lineage kinase domain-like protein; Bax, Bcl-2-associated X protein; Bid, BH3 interacting-domain death agonist; Bcl-2, B-cell lymphoma 2; Cyt-c, cytochrome-c; Apaf-1, apoptotic protease activating factor-1; Smac, second mitochondria-derived activator of caspase; IAP, inhibitor of apoptosis; ULK1, Unc-51-like kinase 1; MOMP, mitochondrial outer membrane permeabilization; AIF, apoptosis-inducing factor; MIF, macrophage migration inhibitory factor; PARP-1, poly-(ADP-ribose)-polymerase 1; LC3, microtubule-associated protein light chain 3; LAMP1, lysosomal-associated membrane protein 1; Rab-7, Ras-related protein-7; Rho-A, Ras homolog family member A; ROCK, Rho-associated coiled-coil containing protein kinase; GSH, glutathione; GPX4, glutathione peroxidase 4; ROS, reactive oxygen species; JNK, Janus kinase; c-JUN, C-junctional protein.

1. Programmed Apoptotic Cell Death in SCI

1) Apoptosis in SCI

Apoptosis is the most typical form of PCD, where cells die systematically in a signal-mediated manner, influenced by a cysteine protease caspase family-mediated cell death leading to planned self-destruction of the cell [25]. It is highly relevant to the progression of SCI. It is immunologically silent that occurs either by intrinsic (mitochondrial), extrinsic (death receptor [DR] triggered), or granzyme/perforin pathway-mediated mechanisms [26]. Inflammatory mediators, free radicals, and excitotoxins are the chemicals that induce necrosis or apoptosis [23]. They feature positional organelle loss, membrane blebbing, cell shrinkage, and DNA fragmentation after condensation [27]. A wide variety of apoptosis in oligodendrocytes and neurons in the damaged spinal cord may produce long-term neurological abnormalities after SCI. Therefore better knowledge is needed to furnish innovative treatment strategies [28].

In recent years, more studies have been done on the role of apoptosis in SCI. Apoptosis is seen both in injured human spinal cords and in animal models. The rat spinal cord showed apoptosis in astrocytes, neurons, microglia, and oligodendroglia [29]. Apoptotic oligodendrocytes are seen in white matter longitudinal filaments [30]. Apoptosis-induced damage to type 3 collagen of endoneurium leads to Wallerian degeneration of the neurons of the spinal cord leading to impairment of neurotransmission and motor functions [31]. Neuronal apoptosis was identified 4 hours postinjury and peaked 8 hours later; in glial cells, it peaked 24 hours later; in oligodendrocytes, in the white matter, it peaked 8 days later. Microglial apoptosis was the least frequent at 24 hours and 5 days after injury but rose quickly and peaked at 8 days [32]. The bulk of apoptotic cells may cluster near the damaged spinal cord’s center, explaining why the lesion area continuously enlarges [23]. Apoptosis is detected in oligodendrocytes with Wallerian degeneration in the chronic phase of SCI [33]. It involves activating components of both downstream and upstream origin in the executioner caspase-3 mediated apoptotic pathway after SCI in rats [34]. Following SCI in animals, the Fas DR pathway was revealed to be significant in microglial, oligodendrocydal, and neuronal apoptosis [35].

Apoptosis is induced by Fas-mediated cysteine protease activation, leading to DNA proteolysis and damage by effector caspases [36]. The function of long noncoding RNAs (lnc-RNAs) and microRNAs (miRNAs) in SCI pathogenesis, including cell death, is also being investigated. MiR-137 targets mitogen-activated protein kinase 2 to inhibit apoptosis after SCI [37]. Using proteomics, Liu et al. [38] discovered Erp29. This critical protein may influence several genes involved in cell death and survival, including Erk and caspase, and ameliorate locomotor activity and function in the rat spinal cord transection model. Gu et al. [39] observed that cutting down long coding XIST RNA reduced neuronal death after SCI by regulating the PTEN/AKT/mTOR pathway and competitively binding miR-494. Another study identified the AKT/mTOR/PTEN signaling pathway implicated in neuronal death after SCI, perhaps through activating the mitochondrial system [40]. It was recently discovered that caspase recruitment domain family member 6 inhibits Caspase-3 signaling and may reduce apoptosis [41]. Understanding apoptosis’s cellular and molecular mechanisms may help identify specific therapeutic targets. Minocycline, CD95 (Fas) ligand antibody blockage, and glycol sphingolipid-induced inducible nitric oxide synthase blocking have all been found to reduce neuronal death and boost the effectiveness of cell transplantation techniques [42]. Zheng et al. [43] observed that miR-142-3p vanquishes apoptosis in rat SCI.

Progranulin deficiency promotes cellular death and neuroinflammation, compromising SCI healing [44]. Zhang et al. [45] discovered that elevated p38 was related to apoptosis and inflammation in a rat SCI contusion model. He also hypothesized that reducing apoptosis and inflammation with the p38 inhibitor SB203580 might help secondary SCI. According to previous research, apoptosis causes tissue lysis and damage post-SCI.

A recent study found that metformin increased β-catenin and brain-derived neurotrophic factor expression, reduced neuron loss and inflammation, and improved functional and motor recovery in rats with SCI [46]. Finding a way to conquer SCI-induced apoptosis has huge therapeutic ramifications. However, the specific pathways triggering apoptotic death of astrocytes, neurons, microglia, and oligodendroglia following SCI are yet unknown [47].

2) Anoikis in SCI

Anoikis is a form of apoptotic PCD; it occurs because of the detachment of cells from the extracellular matrix (ECM) and is extensively observed in the degradation of oligodendrocytes and Schwann cells [48].

Inappropriate or inadequate interactions between cells and the matrix trigger it. The altered cytoskeletal dynamics are believed to interact with a critical prosurvival effector integrin. It leads to impaired ECM remodeling and myelin degeneration which worsens the injury and delays recovery [49]. Cell anoikis impedes recovery by aggravating CNS damage and impairing synaptic plasticity and other CNS activities [50]. Immunosuppression and neuroinflammation are 2 significant factors that contribute to anoikis promoting injury progression. To fasten spinal cord regeneration, adult stem cells are generally injected into a damaged location with high inflammation and poor vascularization [51,52].

Moreover, the lack/absence of ECM leads to post-traumatic cavity formation. Several studies indicate that after transplantation, the number of surviving stem cells decreases considerably in SCI models because of the death of cells by anoikis [53]. In the injury, enzymes are released, which lead to dysfunction and detachment of the ECM cells leading to anoikis; SCI may trigger the neuronal damage by anoikis and enhance the SCI progression. Anoikis inhibition might be the effective strategy to protect the PCD-induced neuronal damages [50]. Biomaterials are already in the research pipeline to prevent this ECM anoikis in SCI. Laminins also help to prevent anoikis in SCI [54].

2. Programmed Nonapoptotic Cell Death in SCI

1) Vacuole-mediated

(1) Autophagy in SCI

Autophagy is a controlled process that is initiated to remove cellular proteins and organelles in significant quantities by transporting them into membrane-bound vesicles to be uptaken by lysosomes to form autophagolysosome to initiate autophagic breakdown. They are formed when vesicles merge with lysosomes, and their contents are destroyed by lysosomal enzymes [55]. Autophagy has been shown to accelerate cellular mortality by activating caspase-reliant apoptosis in specific cells [56]. The PI3K/Akt/mTOR signaling pathway is essential in autophagy [57]. Recent research suggests that the lysosomal compartment plays a protective function in the oxidative stress response [58]. Increased autophagy has been documented after SCI, and emerging evidence suggests autophagy may help preserve neuronal and astrocytic cells from death after SCI, supported by the presence of autophagosomes in cultured and wild-type neurons [59]. However, the influence of autophagy in post-SCI neurodegeneration has been hotly contested, with mixed results from earlier SCI investigations.

Autophagy has been proposed as a potential SCI treatment target by specific studies. Metformin has been shown to protect against SCI by increasing autophagy [60]. He at al. [61] cultured CNS neurons and increased autophagy that stabilized microtubules by degradation of SCG10 (superior cervical ganglion protein 10) and increasing axon development. Axon retraction was reduced, axon regeneration increased, and functional recovery improved in SCI. Astrocyte autophagy flux may increase neurological repercussions, neuronal death, and survival. Many researchers have attempted to relate autophagy with apoptosis. Inducing autophagy protects against apoptosis in mice with acute SCI [62]. Autophagy also protects neurons from endoplasmic reticulum (ER) stress. Therefore its breakdown during SCI may cause ER stress-induced neuronal death [63]. Autophagy may protect spinal cord neurons against apoptosis, which may help SCI neuron survival by incorporating beclin-1 [64]. A contrasting research report found that lowering autophagosome biogenesis enhances spontaneous functional recovery by reducing distant axonal degeneration in SCI patients [65].

Recent research found that LC3+ cells increased considerably at the scar site after the rat spinal cord hemisection model, showing that autophagic cell death often occurs in injured neuronal tissue after SCI [66]. As Purkinje cells die off, phosphorylated MAP1B accumulates in their axonal dystrophic swellings and binds to LC3 at high levels. Therefore, MAP1B-LC3 interaction may contribute to controlling LC3-associated autophagosomes in neurons, especially in axons, under physiological and pathological situations [67]. ABT888, a poly (ADP-ribose) polymerase inhibitor, has recently been shown to protect against SCI by suppressing autophagy [68]. Because of this, autophagy may have both protective and harmful features in SCI. Understanding autophagy’s function in SCI may lead to creating a pleiotropic therapy that targets several pathways and types during the degenerative phase of SCI [69].

(2) Paraptosis in SCI

Paraptosis is another form of PCD, where the cell swells and develops large bubbles or vehicles with the cellular liquid trapped inside and eventually dying off. It occurs because of an imbalance in redox or ion homeostasis [70]. Due to cytoplasmic vacuolation, a novel nonapoptotic and caspase-independent PCD is characterized by ER and mitochondrial dilatation [71]. Previous studies demonstrated a paraptotic response targeting the nucleus in response to paraptosis [72,73]. Some study suggests that cycloheximide and aryl hydrocarbon receptor-interacting protein-1 (AIP-1) may alter paraptosis [74]. Nutlin-3/bortezomib may also disrupt proteostasis to induce long-term structural/functional changes in the mitochondrial and ER, causing mitochondrial/ER stress and, ultimately, cell death via paraptosis [75].

As a consequence, nothing is known about paraptosis in SCI. Increased p44 expression in the CNS is connected to neuronal death and insulin-like growth factor 1 receptor activation through autophagy and paraptosis [76]. Active microglia may lead to neuronal death with characteristics like vacuolation after the caspase cascade has been halted [77]. Studying the activated microglial role in paraptosis might be an exciting new technique. While paraptosis research has advanced, many questions remain. Paraptosis has not been widely investigated in connection to SCI, indicating that additional study is required.

(3) Other minor vacuole-mediated cell death pathways in SCI

Two other critical vacuole-mediated pathways apart from autophagy and paraptosis may have some link in SCI progression. They are entosis and methuosis. Entosis is a novel and interesting nonapoptotic PCD where rather than a cell being swallowed after it is dead, one viable cell actively invades or is pushed into a neighboring cell and dies afterwards, making this process unique. The internalized cell resides in some vacuole structure. Entosis is not restricted to interactions between just 2 cells but can occur between 3 cells or sometimes more [78]. Entotic cell engulfment led to damage in ECM like anoikis; however, their functional process is different. Entosis is one of the cell's cannibalistic behaviors, killing the neighbor cells with the help of the E-cadherin receptor [79]. There has been no direct research approach to link entosis with SCI. However, entosis have been observed when embryonic stem cells have been cultured with mesenchymal stem cells [80]. So, it may hamper stem cell-based spinal regeneration approaches.

Methuosis is nonapoptotic cell death; the mechanism of cell death is related to cytoplasmic fluid displacement by large vacuoles generated by macropinosomes. Rab5 and Rab7 GTPase proteins are involved in the transportation of vacuoles. There is currently no evidence to link methuosis with SCI. However, methamphetamine leads to the death of the neurons in the central nervous system via methuosis [81]. Entosis and methuosis are the new domain for SCI that researchers can approach to bring the novel idea to avoid neuronal damage during SCI.

2) Mitochondria-mediated

(1) Mitoptosis in SCI

Mitochondria is an essential organ to produce energy for cell division and homeostasis. Mitoptosis, also known as mitochondrial suicide, occurs when the mitochondria divide and fuse, cutting off the adenosine triphosphate (ATP) supply and leading to apoptosis and autophagy [82,83]. As a result, they transform into autophagosomes or mitoptotic entities and are ejected. Hence, mitoptosis is a mitochondrial death mechanism rather than a cell death mechanism. However, the high fission or fusion breaks mitochondria apart, ultimately leading to cell death [84]. When BAK/BAX permeabilize the outer mitochondrial membrane proteins, they release a protein called deafness-dystonia peptide (DDP), also known as translocase of inner mitochondrial membrane 8a (TIMM8a) that attaches to cytoplasmic DRP1 to bring DRP1 into the mitochondria to promote mitochondrial fission [85]. A thorough analysis using electron microscopy, as well as the imaging of fragmented mitochondria with mitochondria-specific dyes (MitoTracker Green, Thermo Fisher Scientific Inc., Waltham, MA, USA) using fluorescence microscopy, may offer information about the existence of mitoptosis. In addition, antibodies targeting TIMM8a/DDP and cytochrome-c are also used [85,86]. Mitoptosis occurs due to changes in the membrane of the mitochondria, membrane condensation with swelling and fragmentation in cristae [83].

Mitoptosis is observed in SCI triggered by Ca²⁺ accumulation in the cellular matrix by glutamate excitotoxicity [86]. To investigate a putative mitochondrial-SCI relationship, Wingrave et al. [87] produced a 40 g/cm force injury in rats by contusion, and 4 hours, 1-cm slices of spinal cord tissue were collected for calcium green (2-AM) staining, western blot, and immunohistochemistry. The penumbra and lesion tissue sections showed free intracellular calcium (Ca²⁺) levels increased following the injury compared to sham-operated (control) rats. After SCI, the mitochondria-mediated cell death pathway was activated in the penumbra and lesion by elevating Bax: Bcl-2 ratio via western blot. Wei et al. observed neural damage attenuation and locomotor function improvement in rats [88].

(2) Parthanatos in SCI

It is a type of caspase-independent PCD activated upon specific types of DNA due to the hyperactivation of the DNA repair gene poly ADP-ribose polymerase 1 (PARP1) [89]. Poly-ADP ribose is (PAR) produced by PARP1 that translocates from the nucleus to the cytoplasm, interacting with mitochondrial proteins and releasing apoptosis-inducing factors (AIFs). Then it couples with the macrophage migration inhibitory factor (MIF). This MIF: AIF complex condenses chromatin and breaks DNA in the nucleus [90]. Unlike apoptosis, intact PARP and its activation are required to initiate parthonatos instead of PARP breakdown. Parthanatos is also unaffected by broad-spectrum caspase inhibitors [91].

Moreover, unlike apoptosis, DNA fragmentation is considerable [92]. Biomarkers for parthanatos include nuclear AIF, PARP-1 activation, and PAR accumulation. Mitochondrial depolarization may be detected using fluorescent probe labelling, proving that the method works [93]. Yang et al. [94] observed by interrupting MIF: AIF interaction by knocking down MIF-provided neuroprotection from oxidative stress-induced parthanatos post-SCI. Secondary damage after an initial traumatic or nontraumatic injury is the primary concern of parthanatos in SCI [95]. In post-SCI damage, metabolic disruption and glutamine excitotoxicity are the 2 frequent biochemical pathways [96]. Before the word pathanatos, glutamine excitotoxicity was widely studied concerning cell death [97]. In vitro and in vivo glutamine excitotoxicity models were developed using kainate, a glutamine analogue. In vitro, kainate-induced neuron death was primarily mediated by parthanatos than apoptosis [98]. The inhibitor of PARP-1, 6-5(H)-phenanthridine (PHE), prevented AIF translocation and overactivation of PARP-1, both of which are associated with parthanatos [99].

PJ34, another PARP-1 inhibitor, reduced kainite excitotoxicity. In kainate-treated mice, PJ34 and PHE had minor impacts on locomotor network damage, showing that some areas of the spinal cord may be resistant to parthanatos. Parthanatos killed most neurons, making them more susceptible to excitotoxicity after SCI. However, glial cells were more resistant to excitotoxicity and perished mainly via apoptosis [100]. Oxidative stress contributes to subsequent SCI damage. The inhibition by a polyadenosine diphosphate-ribose polymerase-1 (PARP-1) inhibitor 3-amniobenzamide may help [96]. Parthanatos has been linked to cell death caused by oxidative stress after damage. In the presence of Mg2+ in a pathological medium simulating metabolic disruption after ischemic SCI in vitro, parthanatos was detected in spinal white matter and partial portions of spinal grey matter [101]. JNK1 and JNK3 have also been linked to parthanatos premitochondrial activation [102].

3) Iron-mediated

(1) Ferroptosis in SCI

The term “Ferroptosis” was coined in 2012 as a nonapoptotic PCD triggered by iron accumulation inside the cell [103]. In ferroptosis, the cell maintains a normal-looking morphology and a normal-sized nucleus devoid of chromatin condensation. System XC- is an amino acid antiporter that helps move l-glutamate inside cells and l-cystine outside cells across the plasma membrane of cells contributing to various human processes [103]. A defect in glutathione peroxidase 4 (GPX4) or system XC- causes a collapse in glutathione-dependent antioxidant defense. For glutathione production, system XC- carries cystine into the cell and converts it to cysteine from the extracellular cystine. To reduce cellular lipid peroxidation, GPX4 may directly catalyze glutathione-lipid hydroperoxide interactions. Leaky gut and GPX4 suppression lead to the accumulation of lipid hydroperoxide that reacts with free iron to form lipid reactive oxygen species (ROS) leading to the death of the cell [104]. It is distinguished from apoptosis by morphology, biochemistry, and genetics [105]. In ferroptosis, ROS grows iron-dependently and has a vital role [106]. An upsurge in the number of studies on ferroptosis in SCI has occurred in the last few years. Ferroptosis has been related to excitotoxicity-induced cell death. GPX4 reduces ferroptosis by promoting motor neuron health and survival. So, ferroptosis suppression by GPX4 is essential [104]. Deferoxamine, a drug of iron toxicity, has been shown in previous studies to lower total Fe2+ ions, caspase-3, IL-1β, and TNF-α expression levels after SCI and inhibit the creation of glial scars and apoptosis from increasing function recovery [107]. Another study on the effect of proanthocyanidins on SCI repair indicated that intraperitoneal injections of proanthocyanidins suppressed ferroptosis, which improved functional recovery after SCI [108].

Ferroptosis may have a substantial role in secondary damage after SCI, and inhibiting this process benefits recovery after SCI, according to these studies. On the other hand, adequate research on the role of ferroptosis in SCI still needs to be done. Research is urgently needed to establish the function of ferroptosis, which may lead to new therapeutic options for SCI in glial scar formation and neuronal death [109].

Copper can induce cell death, also termed cuproptosis. FDX1-mediated mitochondrial proteotoxic stress causes cuproptosis. FDX1 converts Cu²⁺ to Cu⁺, boosting lipoylation and aggregation of mitochondrial TCA cycle enzymes (particularly DLAT). In addition, FDX1 inactivates Fe-S cluster proteins. Cu importers (SLC31A1) and exporters (ATP7B) change intracellular Cu⁺ levels to impact cuproptosis sensitivity [110]. Even though it has not been linked with SCI, Enge et al. [111] found elevated Cu concentrations in skeletal muscle and the spinal cord in the presymptomatic stage, which worsened with disease development in the SOD1G93A-mutant mice amyotrophic lateral sclerosis model.

4) Immune factors mediated

(1) Pyroptosis in SCI

Pyroptosis is a nonapoptotic PCD that happens in immune cells as a response when intracellular pathogens release inflammatory signals. Infected macrophages’ inflammatory sensors, like NOD-like receptors (NLRs), detect flagellin molecules in pathogens and induce the development of multiprotein complex inflammasomes, which then activate caspase1 [112]. When activated, caspase1 causes membrane hole formation by cleaving gasdermin D, causing the cell membrane to tear [113]. DNA condensation and fragmentation are also seen throughout the process. Furthermore, bacterial lipopolysaccharide (LPS) directly activates caspase11, causing pyroptosis [114]. Pyroptosis can be determined through gasdermin D cleavage through western blot analysis, IL-1 through caspase activation, and visualization of membrane integrity loss through fluorescence microscopy and the quantification of released cytoplasmic lactate dehydrogenase [115].

Epithelial cells, neurons, and pyroptotic keratinocytes, as well as myeloid-derived professional phagocytes such as DCs and macrophages, all, have been identified to show pyroptosis. In addition, pyroptosis has been linked to antibacterial and inflammatory responses during infection [116].

Inflammasomes containing the caspase-1 enzyme have been found to inhibit pyroptosis in the amygdala kindling model of neurological illness [117]. Silencing Nucleotide-binding oligomerization domain-1 (NLRP1) or caspase-1 also decreased pyroptosis in rats [118]. Deficient microglial voltage-gated proton channels may inhibit NLRP3-induced neuronal pyroptosis. Sevoflurane-induced neuronal pyroptosis is connected to the Bach1/Nrf2/Erk1 signaling pathway [119]. Streptococcus pneumoniae can cause pyroptosis in murine microglia, requiring the NLRP3 inflammasome, which activates caspase-1 [120]. The function of pyroptosis in SCI pathogenesis is unknown. Pyroptosis and the inflammatory response to SCI should be explored further.

(2) Netosis in SCI

Netosis is a nonapoptotic PCD caused by pathogenic infections or their components. It is most frequent in immune cells, notably neutrophils. It causes the nucleus or mitochondria of neutrophils to generate extracellular traps (NETs) composed of modified chromatin-coated neutrophil DNA and bactericidal proteins from granules and cytoplasm [121]. The most common type is suicidal netosis, where neutrophils die after releasing NETs [122]. When neutrophils recognize pathogen-associated molecular pattern signals from pathogens, that activates the mitogen-activated protein kinase complex to produce protein kinase (PKC). PKC activates NADPH oxidase, causing ROS generation. Increased Ca²⁺ levels in mitochondria cause mitochondrial permeability transition pore (mPTP) to open and release mitochondrial ROS (mtROS) [123]. Mitochondrial dynamin like GTPase (OPA1) ensures the production of NAD+, which is eventually converted to nicotinamide adenine dinucleotide (NADH) through glycolysis. Lastly, NADH transports electrons in the mitochondrial electron transport complex, which upon activation, supplies ATP for NET synthesis [124].

ROS with mtROS causes azurosome release by rupturing azurophil granules. Neutrophil elastase (NE) and myeloperoxidase (MPO) release and translocates along with a gene named Peptidyl arginine deiminase 4 (PADI4) in the nucleus [125]. MPO generates HOCl- to start secondary injury progression, and NEs cleave the Gasdermin D pore at the nuclear membrane to release NETs [126]. PADI4 enters the nucleus and causes chromatin decondensation by citrullinating histones (H3, H2A, and H4) and inhibiting glutaredoxin 1 to disrupt cytoskeletal dynamics of the membrane [127]. Another type of netosis, also known as vital netosis, is where the neutrophil does not die. It is believed to occur by the NET formation of mitochondrial DNA rather than the nuclear DNA of neutrophils. It occurs by the Activation of Toll-like receptor 4 (TLR4) and is regulated by small conductance calcium-activated potassium (SK3) channels [128]. Elevated cytosolic Ca²⁺ increases in SCI pathology promote complex 1 activity and ATP and ROS generation [129]. Tissue damage, Hypoxia, oedema, and tissue damage cause the synthesis of the first soluble mediator of ROS [130]. The role of ROS in developing networked systems is significant. Because of this, SCI may induce NETosis. The mitochondrial calcium uniporter also allows Ca²⁺ into the mitochondria. Ca²⁺ levels inside cells may promote membrane permeability. NADPH Oxidase activation or other nonoxidative mechanisms connected to mPTP. Thus, NETs develop throughout the SCI process. Neutrophils infiltrate the spinal cord following SCI [131]. These cytotoxic elements cause more extensive lesions and decrease neurological function. MPO increases neutrophil infiltration, causing secondary injury and slowing SCI recovery [132].

Swelling oedema in the spinal cord astrocytes may cause poor functional recovery and treatment resistance following SCI. Rat spinal cord astrocytic oedema was reduced when oxygen-glucose deprivation and reperfusion (OGD/R) were combined with the high mobility group box protein 1 (HMGB1) shRNA or ethyl-pyruvate treatment. Conversely, when OGD/R was applied to spinal cord astrocytes, HMGB1 increased aquaporin-4 (AQP4) expression and cell swelling through HMGB1/TLR4/nuclear factor-kappa B (NF-κB) signaling. Inhibitors of TLR4 and NF-κB have also been demonstrated to reduce activation effects [133]. TLR4 induces NETosis and increases damage after cerebral ischemia and thrombosis [134]. Therefore, NET development may affect SCI damage. However, no proof exists. However, some research suggests neutrophils may benefit tissue regeneration in SCI since their inflammatory activity may promote healing [135]. Various unanswered concerns surround neutrophil activity in SCI. To get new insights into traumatic brain damage, further study of their cellular and molecular pathways is necessary (SCI).

5) Other factors mediated

(1) Necroptosis in SCI

Also known as programmed necrosis, it activates receptorinteracting protein kinases (RIPKs) by Activation and crosstalk through many signaling pathways. RIPKs are triggered by the employment of several cell surface receptors to macromolecular complexes: T-cell receptors, DRs, and TLRs. RIPK1 and RIPK3 are essential components of the necrosome. RIPK3 phosphorylates the downstream molecule mixed lineage kinase domainlike protein (MLKL), causing MLKL oligomerization. An oligomerized MLKL enters the cell membrane and permeabilizes it, causing cell death [136]. Furthermore, regulatory factors of DNA-dependent activators of interferon synthesized after viral infestation, double-stranded viral DNA, and cytosolic DNA sensors activate RIP3-dependent necroptosis. It exhibits necrotic morphology, including membrane rupture and organelle loss. An increasing amount of research shows that, unlike necrosis, necroptosis is caspase-independent [137]. It is relevant and well established in ischemic brain damage, viral myocardial infarction, and neurodegenerative diseases [138]. The most well-studied necroptosis pathway is TNF-R1 binding to TNF [139]. Research suggests necroptosis is involved in an intracellular signaling cascade involving MLKL and RIP1/3 kinase [136]. RIP1 kinase activity is required for necroptosis activation. Holler et al. [140] discovered that proteasome subunit beta type-4 controls the RIP3 and MLKL pathways using TNF-induced necroptosis cell culture. Wang et al. [141] discovered necrostatin-1 (NEC-1), a novel small molecule suppresses necroptosis by modulation of the formation of protein complexes of RIPK1 and RIPK3 and by recruiting RIP1/3–MLKL. After SCI, Nec-1 improved the histopathology and functional impairments, indicating that necroptosis may contribute to brain cell death. Thus, Nec-1 may be used to treat SCI [141].

Increasing evidence links SCI necroptosis to inflammation. The ER of necroptotic microglia/macrophages can modulate SCI-induced inflammation [142]. Fan et al. [143] discovered that M1 macrophages/microglia might induce necroptosis in reactive astrocytes through the MyD88/TLR signaling pathway. Smad ubiquitination regulatory factor-1 (Smurf1) may promote neuron necroptosis following LPS-induced neuroinflammation, suggesting it might be a therapeutic target [144]. After spinal cord damage, necroptosis-induced glial and neuronal cell death has been reported. Activating necroptosis in the CNS may cause cell death and tissue damage. Despite substantial research into necroptosis after SCI, our knowledge is limited. Secondary damage can only be addressed if necroptosis is linked to SCI etiology [145].

(2) Other minor pathways in SCI

Other minor pathways may also lead to SCI progression. Oxieptosis is a novel nonapoptotic PCD that is triggered by the accumulation of ROS. Kelch-like ECH-associated protein 1 (KEAP1) C-terminal cysteines are oxidized by moderate ROS levels, causing degradation of the KEAP1-NRF2 complex and nuclear translocation of NRF2 [146]. Antioxidant genes are produced by Nrf2 that help to remove ROS from the nucleus. High amounts of intracellular ROS trigger the production of phosphoglycerate mutase family member 5 by KEAP1, which dephosphorylates apoptosis-inducing factor 1 (AIFM1) at the Ser116 position after binding to it, ultimately leading to this kind of cell death [147]. ROS significantly affects the primary and secondary injury progression for SCI [148]. Due to ischemic injury at the primary injury site, free ROS gets generated, which links with the disruption in Nrf2 translocation and decreasing neuronal pH and form of mPTP complex [72,149]. So even though there is no current research linking oxieptosis to SCI, it is a starting point to start many cell death pathways relevant to SCI. So, it is a hot topic for researchers to explore.

pH has a significant role in the progression of cell death in SCI. Alkaliptosis is a new pH-dependent cell death relevant to many diseases [150]. Tang et al. [151] define alkaliptosis as pH-mediated, N-acetyl cysteine-mediated, drug-induced cell death. Scientists have established that alkalinization of the cellular milieu with sodium hydroxide promotes cell death using NF-kB. Unlike ferroptosis and necrosis, alkaliptosis is a chemical process. NF-kB activation may prevent alkaliptosis [152]. The Nrf2/HO-1 signaling pathway may activate proinflammatory and apoptosis-inhibitory genes. Over or underexpression of the Nrf2/HO-1 signaling pathway has antiapoptotic effects that can be utilized against this type of cell. Currently, there is no research done to link alkaliptosis with SCI. Furlong et al. [153] showed that intracellular acidification induces apoptosis by stimulating IL-1β converting enzyme like protease activity. In the isolated spinal cord, Jalalvand et al. [154] showed that both increased and decreased pH reduced the locomotor burst rate, proving a possible link between alkaliptosis and SCI. Treatment strategies can be built around it as it heavily depends upon the NF-kB pathway [155].

Autoschizis is another bizarre type of cell death where the cell develops cracks. These cracks develop inside the cell organism, followed by getting destroyed by proteases that also develop inside the cell. The standard cell remains unaffected, but the cracked cells die off [156]. There is currently no link between autoschizis and SCI. However, it is a potent necrosome trigger that may contribute to the necrosis and necroptosis progression in SCI [157].

3. Nonprogrammed Nonapoptotic Cell Death

1) Nonprogrammed necrosis in SCI

Necrosis is a nonprogrammed type of cell death triggered by toxins, physical injuries, and infections disrupting ionic pumps leading to Ca²⁺ influx, resulting in morphological alterations such as cytoplasmic swelling (oncosis), consequential intracellular organelle loss with little to no chromatin condensation, and plasma membrane rupture [158]. It starts with the acute phase comprising a variety of mechanisms, including ionic imbalance and glutamate excitotoxicity, toxic blood component buildup, the release of proinflammatory cytokine by lymphocytes and neutrophils, ATP depletion, and free radical production [159]. As the damage continues, in the subacute phase, surviving axonal demyelination, neuronal apoptosis, axonal bulb retraction (dieback), Wallerian degeneration, glial scar formation surrounding the injury site, and matrix remodeling occur. In the chronic damage phase, further changes occur, such as maturation of the glial scar, increasing axonal retraction bulb (dieback), and creating a cystic cavity [160]. It is common in trauma, ischemia, and potentially certain kinds of neurodegenerative conditions. It is typically regarded as a passive process that requires very little energy yet does not need de novo macro molecular synthesis [161]. The process of cell death is a continuum of apoptosis and necrosis. Variable levels of crosstalk harmony between coexisting apoptotic and necrotic processes might contribute to neuronal death along this spectrum [162]. The contribution of necrosis in SCI pathology has been well established in both in vitro and in vivo models of acute and chronic SCI [163]. Acute SCI results in necrosis, known as progressive hemorrhagic necrosis. It is a poorly understood pathological process marked by necrosis and bleeding that results in severe cystic cavitation of the spinal cord, profound neurological impairment, and spinal cord tissue loss [164]. A necrosis initiator gene, TNF-α, produces death in oligodendrocytes in the spinal and supraspinal region [165]. Its antagonist significantly reduced oligodendroglial necrosis in SCI [166]. Excessive N-methyl-D-aspartate receptor activation in neurons during glutamate-induced excitotoxicity may result in necrotic cell death and progression of secondary injury [167]. These secondary processes contribute to the evolution of pathological abnormalities in severe injuries, from central hemorrhagic necrosis involving predominantly grey matter to infarction of both white and grey matter proximally and distally at the injury site. Less severe damage changes axons and myelin [168] (Table 1).

Table 1.

Different cell death Pathways associated with spinal cord injury and their therapeutic interventions

CONCLUSION AND FUTURE PERSPECTIVE

The ensuing cascade of cell death after CNS injury or ischemia has long been considered a target for neuroprotective drugs to preserve tissue and function. Defects in one or more cell death processes are connected to various spinal cord injuries, including neurodegenerative conditions involving abnormal cell destruction. The regulators and signaling pathways of the various cell death mechanisms continue to be appealing therapeutic targets that have the potential to serve as the foundation for translational research that may result in improvements for patients afflicted with these disorders. As a concluding statement, we can say that a significant amount of additional research, including both fundamental works in studies of animal models involving clinical trials, is required to acquire a more in-depth knowledge of the various processes modulating cell death in SCI. Many cell death pathways for axonal/neuronal regeneration and proinflammatory signaling-induced secondary injury in SCI are undiscovered. This review thus expands the extent of the cell death pathways in the SCI, and knowledge must be used to make revolutionary advancements in treating these illnesses.

Notes

Conflict of Interest

The authors have nothing to disclose.

Funding/Support

This study received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author Contribution

Conceptualization: HK; Project administration: HK; Writing - original draft: LG; Writing - review & editing: NS, HK.

Acknowledgements

We acknowledge the financial assistance in Ph.D. fellowship to LG and NS from the Ministry of Chemicals and Fertilizers, Government of India.

References

1. Bennett J, M Das J, Emmady PD. Spinal cord injuries. In: StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2023.

2. Kang Y, Ding H, Zhou HX, et al. Epidemiology of worldwide spinal cord injury: a literature review. J Neurosurg 2018;6:1–9.

3. van Den Hauwe L, Sundgren PC, Flanders AE. Spinal trauma and spinal cord injury (SCI). In: Hodler J, Kubik-Huch RA, von Schulthess GK, editors. Diseases of the brain, head and neck, spine 2020–2023: diagnostic imaging [Internet]. Cham (CH): Springer; 2020. Chapter 19.

4. Gadot R, Smith DN, Prablek M, et al. Established and emerging therapies in acute spinal cord injury. Neurospine 2022;19:283–96.

5. Tran AP, Warren PM, Silver J. The biology of regeneration failure and success after spinal cord injury. Physiol Rev 2018;98:881–917.

6. Anjum A, Yazid MD, Fauzi Daud M, et al. Spinal cord injury: pathophysiology, multimolecular interactions, and underlying recovery mechanisms. Int J Mol Sci 2020;21:7533.

7. Wang HF, Liu XK, Li R, et al. Effect of glial cells on remyelination after spinal cord injury. Neural Regen Res 2017;12:1724–32.

8. Geden MJ, Deshmukh M. Axon degeneration: context defines distinct pathways. Curr Opin Neurobiol 2016;39:108–15.

9. Shi Z, Yuan S, Shi L, et al. Programmed cell death in spinal cord injury pathogenesis and therapy. Cell Prolif 2021;54:e12992.

10. Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun 2005;73:1907.

11. Ray SK. Modulation of autophagy for neuroprotection and functional recovery in traumatic spinal cord injury. Neural Regen Res 2020;15:1601–12.

12. Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 2018;25:486–541.

13. Green DR, Llambi F. Cell death signaling. Cold Spring Harb Perspect Biol 2015;7:a006080.

14. Yan G, Elbadawi M, Efferth T. Multiple cell death modalities and their key features. World Acad Sci J 2020;2:39–48.

15. Bhagwani A, Chopra M, Kumar H. Spinal cord injury provoked neuropathic pain and spasticity, and their GABAergic connection. Neurospine 2022;19:646–68.

16. Oyinbo CA. Secondary injury mechanisms in traumatic spinal cord injury: a nugget of this multiply cascade. Acta Neurobiol Exp (Wars) 2011;71:281–99.

17. Vallès M, Mearin F. Pathophysiology of bowel dysfunction in patients with motor incomplete spinal cord injury: comparison with patients with motor complete spinal cord injury. Dis Colon Rectum 2009;52:1589–97.

18. Garcia E, Aguilar-Cevallos J, Silva-Garcia R, et al. Cytokine and growth factor activation in vivo and in vitro after spinal cord injury. Mediators Inflamm 2016;2016:9476020.

19. Alizadeh A, Dyck SM, Karimi-Abdolrezaee S. Traumatic spinal cord injury: an overview of pathophysiology, models and acute injury mechanisms. Front Neurol 2019;10:282.

20. Sharma HS. Early microvascular reactions and blood-spinal cord barrier disruption are instrumental in pathophysiology of spinal cord injury and repair: novel therapeutic strategies including nanowired drug delivery to enhance neuroprotection. J Neural Transm (Vienna) 2011;118:155–76.

21. Lekli I, Haines DD, Balla G, et al. Autophagy: an adaptive physiological countermeasure to cellular senescence and ischaemia/reperfusion-associated cardiac arrhythmias. J Cell Mol Med 2017;21:1058–72.

22. Song B, Zhou T, Liu J, et al. Involvement of programmed cell death in neurotoxicity of metallic nanoparticles: recent advances and future perspectives. Nanoscale Res Lett 2016;11:484.

23. Lu J, Ashwell KW, Waite P. Advances in secondary spinal cord injury: role of apoptosis. Spine (Phila Pa 1976) 2000;25:1859–66.

24. Zhu K, Xu W, Han D, et al. Effect of sirtuin-1 and Wnt/β-catenin signaling pathway in rat model of spinal cord injury. Comput Math Methods Med 2022;2022:1799607.

25. Maiuri MC, Zalckvar E, Kimchi A, et al. Self-eating and self-killing: crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 2007;8:741–52.

26. Thornton C, Leaw B, Mallard C, et al. Cell death in the developing brain after hypoxia-ischemia. Front Cell Neurosci 2017;11:248.

27. Matassov D, Kagan T, Leblanc J, et al. Measurement of apoptosis by DNA fragmentation. Methods Mol Biol 2004;282:1–17.

28. Zhang N, Yin Y, Xu SJ, et al. Inflammation & apoptosis in spinal cord injury. Indian J Med Res 2012;135:287–96.

29. Yong C, Arnold PM, Zoubine MN, et al. Apoptosis in cellular compartments of rat spinal cord after severe contusion injury. J Neurotrauma 1998;15:459–72.

30. Li GL, Brodin G, Farooque M, et al. Apoptosis and expression of Bcl-2 after compression trauma to rat spinal cord. J Neuropathol Exp Neurol 1996;55:280–9.

31. Gaudet AD, Popovich PG, Ramer MS. Wallerian degeneration: gaining perspective on inflammatory events after peripheral nerve injury. J Neuroinflammation 2011;8:110.

32. Liu XZ, Xu XM, Hu R, et al. Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci 1997;17:5395–406.

33. Emery E, Aldana P, Bunge MB, et al. Apoptosis after traumatic human spinal cord injury. J Neurosurg 1998;89:911–20.

34. Springer JE, Azbill RD, Knapp PE. Activation of the caspase-3 apoptotic cascade in traumatic spinal cord injury. Nat Med 1999;5:943–6.

35. Yu WR, Fehlings MG. Fas/FasL-mediated apoptosis and inflammation are key features of acute human spinal cord injury: implications for translational, clinical application. Acta Neuropathol 2011;122:747–61.

36. Rowland JW, Hawryluk GW, Kwon B, et al. Current status of acute spinal cord injury pathophysiology and emerging therapies: promise on the horizon. Neurosurg Focus 2008;25:E2.

37. Gao L, Dai C, Feng Z, et al. MiR-137 inhibited inflammatory response and apoptosis after spinal cord injury via targeting of MK2. J Cell Biochem 2018;119:3280–92.

38. Liu R, Zhao W, Zhao Q, et al. Endoplasmic reticulum protein 29 protects cortical neurons from apoptosis and promoting corticospinal tract regeneration to improve neural behavior via caspase and Erk signal in rats with spinal cord transection. Mol Neurobiol 2014;50:1035–48.

39. Gu S, Xie R, Liu X, et al. Long Coding RNA XIST Contributes to neuronal apoptosis through the downregulation of AKT phosphorylation and is negatively regulated by miR494 in rat spinal cord injury. Int J Mol Sci 2017;18:732.

40. Wang Z, Zhou L, Zheng X, et al. Autophagy protects against PI3K/Akt/mTOR-mediated apoptosis of spinal cord neurons after mechanical injury. Neurosci Lett 2017;656:158–64.

41. Wang JL, Luo X, Liu L. Targeting CARD6 attenuates spinal cord injury (SCI) in mice through inhibiting apoptosis, inflammation and oxidative stress associated ROS production. Aging (Albany NY) 2019;11:12213–35.

42. Beattie MS. Inflammation and apoptosis: linked therapeutic targets in spinal cord injury. Trends Mol Med 2004;10:580–3.

43. Zheng J, Kuang J, Zhang X, et al. miR-142-3p suppresses apoptosis in spinal cord-injured rats. Transl Neurosci 2020;11:105–15.

44. Wang C, Zhang L, Ndong JC, et al. Progranulin deficiency exacerbates spinal cord injury by promoting neuroinflammation and cell apoptosis in mice. J Neuroinflammation 2019;16:238.

45. Zhang HW, Ding JD, Zhang ZS, et al. Critical role of p38 in spinal cord injury by regulating inflammation and apoptosis in a rat model. Spine (Phila Pa 1976) 2020;45:E355–63.

46. Zhang T, Wang F, Li K, et al. Therapeutic effect of metformin on inflammation and apoptosis after spinal cord injury in rats through the Wnt/β-catenin signaling pathway. Neurosci Lett 2020;739:135440.

47. Fan B, Wei Z, Feng S. Progression in translational research on spinal cord injury based on microenvironment imbalance. Bone Res 2022;10:35.

48. Abe Y, Yamamoto T, Sugiyama Y, et al. “Anoikis” of oligodendrocytes induced by Wallerian degeneration: ultrastructural observations. J Neurotrauma 2004;21:119–24.

49. Adeshakin FO, Adeshakin AO, Afolabi LO, et al. Mechanisms for modulating anoikis resistance in cancer and the relevance of metabolic reprogramming. Front Oncol 2021;11:626577.

50. Sater AP, Rael LT, Tanner AH, et al. Cell death after traumatic brain injury: detrimental role of anoikis in healing. Clin Chim Acta 2018;482:149–54.

51. Ma YH, Liang QY, Ding Y, et al. Multimodal repair of spinal cord injury with mesenchymal stem cells. Neurospine 2022;19:616–29.

52. Yu H, Yang S, Li H, et al. Activating endogenous neurogenesis for spinal cord injury repair: recent advances and future prospects. Neurospine 2023;20:164–80.

53. Zurita M, Otero L, Aguayo C, et al. Cell therapy for spinal cord repair: optimization of biologic scaffolds for survival and neural differentiation of human bone marrow stromal cells. Cytotherapy 2010;12:522–37.

54. Domogatskaya A, Rodin S, Tryggvason K. Functional diversity of laminins. Annu Rev Cell Dev Biol 2012;28:523–53.

55. Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. Science 2000;290:1717–21.

56. Boya P, González-Polo RA, Casares N, et al. Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 2005;25:1025–40.

57. Jung CH, Ro SH, Cao J, et al. mTOR regulation of autophagy. FEBS Lett 2010;584:1287–95.

58. Chen HC, Hsu PW, Tzaan WC, et al. Effects of the combined administration of vitamins C and E on the oxidative stress status and programmed cell death pathways after experimental spinal cord injury. Spinal Cord 2014;52:24–8.

59. Maday S, Holzbaur EL. Autophagosome biogenesis in primary neurons follows an ordered and spatially regulated pathway. Dev Cell 2014;30:71–85.

60. Zhang D, Xuan J, Zheng BB, et al. Metformin improves functional recovery after spinal cord injury via autophagy flux stimulation. Mol Neurobiol 2017;54:3327–41.

61. He M, Ding Y, Chu C, et al. Autophagy induction stabilizes microtubules and promotes axon regeneration after spinal cord injury. Proc Natl Acad Sci U S A 2016;113:11324–9.

62. Tang P, Hou H, Zhang L, et al. Autophagy reduces neuronal damage and promotes locomotor recovery via inhibition of apoptosis after spinal cord injury in rats. Mol Neurobiol 2014;49:276–87.

63. Liu S, Sarkar C, Dinizo M, et al. Disrupted autophagy after spinal cord injury is associated with ER stress and neuronal cell death. Cell Death Dis 2015;6:e1582.

64. Wang ZY, Lin JH, Muharram A, et al. Beclin-1-mediated autophagy protects spinal cord neurons against mechanical injury-induced apoptosis. Apoptosis 2014;19:933–45.

65. Bisicchia E, Latini L, Cavallucci V, et al. Autophagy inhibition favors survival of rubrospinal neurons after spinal cord hemisection. Mol Neurobiol 2017;54:4896–907.

66. Kanno H, Ozawa H, Sekiguchi A, et al. Induction of autophagy and autophagic cell death in damaged neural tissue after acute spinal cord injury in mice. Spine (Phila Pa 1976) 2011;36:E1427–34.

67. Wang QJ, Ding Y, Kohtz DS, et al. Induction of autophagy in axonal dystrophy and degeneration. J Neurosci 2006;26:8057–68.

68. Casili G, Campolo M, Lanza M, et al. Role of ABT888, a novel poly(ADP-Ribose) polymerase (PARP) inhibitor in countering autophagy and apoptotic processes associated to spinal cord injury. Mol Neurobiol 2020;57:4394–407.

69. Liao HY, Wang ZQ, Ran R, et al. Biological functions and therapeutic potential of autophagy in spinal cord injury. Front Cell Dev Biol 2021;9:761273.

70. Fontana F, Raimondi M, Marzagalli M, et al. The emerging role of paraptosis in tumor cell biology: Perspectives for cancer prevention and therapy with natural compounds. Biochim Biophys Acta Rev Cancer 2020;1873:188338.

71. Wang Y, Wen X, Zhang N, et al. Small-molecule compounds target paraptosis to improve cancer therapy. Biomed Pharmacother 2019;118:109203.

72. Xue J, Li R, Zhao X, et al. Morusin induces paraptosis-like cell death through mitochondrial calcium overload and dysfunction in epithelial ovarian cancer. Chem Biol Interact 2018;283:59–74.

73. Pierroz V, Rubbiani R, Gentili C, et al. Dual mode of cell death upon the photo-irradiation of a RuII polypyridyl complex in interphase or mitosis. Chem Sci 2016;7:6115–24.

74. Wang WB, Feng LX, Yue QX, et al. Paraptosis accompanied by autophagy and apoptosis was induced by celastrol, a natural compound with influence on proteasome, ER stress and Hsp90. J Cell Physiol 2012;227:2196–206.

75. Lee DM, Kim IY, Seo MJ, et al. Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis. Exp Mol Med 2017;49:e365.

76. Pehar M, O’Riordan KJ, Burns-Cusato M, et al. Altered longevity-assurance activity of p53:p44 in the mouse causes memory loss, neurodegeneration and premature death. Aging Cell 2010;9:174–90.

77. Tanabe K, Nakanishi H, Maeda H, et al. A predominant apoptotic death pathway of neuronal PC12 cells induced by activated microglia is displaced by a non-apoptotic death pathway following blockage of caspase-3-dependent cascade. J Biol Chem 1999;274:15725–31.

78. Le Bot N. Entosis: cell death by invasion. Nat Cell Biol 2007;9:1346.

79. Krishna S, Overholtzer M. Mechanisms and consequences of entosis. Cell Mol Life Sci 2016;73:2379–86.

80. Sottile F, Aulicino F, Theka I, et al. Mesenchymal stem cells generate distinct functional hybrids in vitro via cell fusion or entosis. Sci Rep 2016;6:36863.

81. Nara A, Aki T, Funakoshi T, et al. Methamphetamine induces macropinocytosis in differentiated SH-SY5Y human neuroblastoma cells. Brain Res 2010;1352:1–10.

82. Lyamzaev KG, Nepryakhina OK, Saprunova VB, et al. Novel mechanism of elimination of malfunctioning mitochondria (mitoptosis): formation of mitoptotic bodies and extrusion of mitochondrial material from the cell. Biochim Biophys Acta 2008;1777:817–25.

83. Jangamreddy JR, Los MJ. Mitoptosis, a novel mitochondrial death mechanism leading predominantly to activation of autophagy. Hepat Mon 2012;12:e6159.

84. Youle RJ, Karbowski M. Mitochondrial fission in apoptosis. Nat Rev Mol Cell Biol 2005;6:657–63.

85. Arnoult D, Rismanchi N, Grodet A, et al. Bax/Bak-dependent release of DDP/TIMM8a promotes Drp1-mediated mitochondrial fission and mitoptosis during programmed cell death. Curr Biol 2005;15:2112–8.

86. Lyamzaev KG, Knorre DA, Chernyak BV. Mitoptosis, twenty years after. Biochemistry (Mosc) 2020;85:1484–98.

87. Wingrave JM, Schaecher KE, Sribnick EA, et al. Early induction of secondary injury factors causing activation of calpain and mitochondria-mediated neuronal apoptosis following spinal cord injury in rats. J Neurosci Res 2003;73:95–104.

88. Lin MW, Fang SY, Hsu JC, et al. Mitochondrial transplantation attenuates neural damage and improves locomotor function after traumatic spinal cord injury in rats. Front Neurosci 2022;16:800883.

89. Wu C, Chen J, Liu Y, et al. Upregulation of PSMB4 is associated with the necroptosis after spinal cord injury. Neurochem Res 2016;41:3103–12.

90. David KK, Andrabi SA, Dawson TM, et al. Parthanatos, a messenger of death. Front Biosci (Landmark Ed) 2009;14:1116–28.

91. Yu SW, Wang H, Poitras MF, et al. Mediation of poly(ADPribose) polymerase-1-dependent cell death by apoptosisinducing factor. Science 2002;297:259–63.

92. Fatokun AA, Dawson VL, Dawson TM. Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. Br J Pharmacol 2014;171:2000–16.

93. Wang Y, Dawson VL, Dawson TM. Poly(ADP-ribose) signals to mitochondrial AIF: a key event in parthanatos. Exp Neurol 2009;218:193–202.

94. Yang D, Shu T, Zhao H, et al. Knockdown of macrophage migration inhibitory factor (MIF), a novel target to protect neurons from parthanatos induced by simulated post-spinal cord injury oxidative stress. Biochem Biophys Res Commun 2020;523:719–25.

95. Kuzhandaivel A, Nistri A, Mazzone GL, et al. Molecular mechanisms underlying cell death in spinal networks in relation to locomotor activity after acute injury in vitro. Front Cell Neurosci 2011;5:9.

96. Wang X, Ge P. Parthanatos in the pathogenesis of nervous system diseases. Neuroscience 2020;449:241–50.

97. Alexander SP, Benson HE, Faccenda E, et al. The concise guide to PHARMACOLOGY 2013/14: overview. Br J Pharmacol 2013;170:1449–58.

98. Kuzhandaivel A, Nistri A, Mladinic M. Kainate-mediated excitotoxicity induces neuronal death in the rat spinal cord in vitro via a PARP-1 dependent cell death pathway (Parthanatos). Cell Mol Neurobiol 2010;30:1001–12.

99. Nasrabady SE, Kuzhandaivel A, Mladinic M, et al. Effects of 6(5H)-phenanthridinone, an inhibitor of poly(ADP-ribose)polymerase-1 activity (PARP-1), on locomotor networks of the rat isolated spinal cord. Cell Mol Neurobiol 2011;31:503–8.

100. Nasrabady SE, Kuzhandaivel A, Nistri A. Studies of locomotor network neuroprotection by the selective poly(ADPribose) polymerase-1 inhibitor PJ-34 against excitotoxic injury to the rat spinal cord in vitro. Eur J Neurosci 2011;33:2216–27.

101. Bianchetti E, Mladinic M, Nistri A. Mechanisms underlying cell death in ischemia-like damage to the rat spinal cord in vitro. Cell Death Dis 2013;4:e707.

102. Muthaiah VPK, Michael FM, Palaniappan T, et al. JNK1 and JNK3 play a significant role in both neuronal apoptosis and necrosis. Evaluation based on in vitro approach using tert-butylhydroperoxide induced oxidative stress in neuro-2A cells and perturbation through 3-aminobenzamide. Toxicol In Vitro 2017;41:168–78.

103. Cao JY, Dixon SJ. Mechanisms of ferroptosis. Cell Mol Life Sci 2016;73:2195–209.

104. Chen L, Hambright WS, Na R, et al. Ablation of the ferroptosis inhibitor glutathione peroxidase 4 in neurons results in rapid motor neuron degeneration and paralysis. J Biol Chem 2015;290:28097–106.

105. Dixon SJ, Lemberg KM, Lamprecht MR, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012;149:1060–72.

106. Ma S, Dielschneider RF, Henson ES, et al. Ferroptosis and autophagy induced cell death occur independently after siramesine and lapatinib treatment in breast cancer cells. PLoS One 2017;12:e0182921.

107. Hao J, Li B, Duan HQ, et al. Mechanisms underlying the promotion of functional recovery by deferoxamine after spinal cord injury in rats. Neural Regen Res 2017;12:959–68.

108. Zhou H, Yin C, Zhang Z, et al. Proanthocyanidin promotes functional recovery of spinal cord injury via inhibiting ferroptosis. J Chem Neuroanat 2020;107:101807.

109. Shen L, Lin D, Li X, et al. Ferroptosis in acute central nervous system injuries: the future direction? Front Cell Dev Biol 2020;8:594.

110. Tang D, Chen X, Kroemer G. Cuproptosis: a copper-triggered modality of mitochondrial cell death. Cell Res 2022;32:417–8.

111. Enge TG, Ecroyd H, Jolley DF, et al. Longitudinal assessment of metal concentrations and copper isotope ratios in the G93A SOD1 mouse model of amyotrophic lateral sclerosis. Metallomics 2017;9:161–74.

112. Bergsbaken T, Fink SL, Cookson BT. Pyroptosis: host cell death and inflammation. Nat Rev Microbiol 2009;7:99–109.

113. Liu X, Zhang Z, Ruan J, et al. Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores. Nature 2016;535:153–8.

114. Lacey CA, Mitchell WJ, Dadelahi AS, et al. Caspase-1 and caspase-11 mediate pyroptosis, inflammation, and control of brucella joint infection. Infect Immun 2018;86:e00361–18.

115. Masuda S, Nakazawa D, Shida H, et al. NETosis markers: quest for specific, objective, and quantitative markers. Clin Chim Acta 2016;459:89–93.

116. Vande Walle L, Lamkanfi M. Pyroptosis. Curr Biol 2016;26:R568–72.

117. Tan MS, Yu JT, Jiang T, et al. The NLRP3 inflammasome in Alzheimer’s disease. Mol Neurobiol 2013;48:875–82.

118. Tan CC, Zhang JG, Tan MS, et al. NLRP1 inflammasome is activated in patients with medial temporal lobe epilepsy and contributes to neuronal pyroptosis in amygdala kindling-induced rat model. J Neuroinflammation 2015;12:18.

119. Li R, Zhang LM, Sun WB. Erythropoietin rescues primary rat cortical neurons from pyroptosis and apoptosis via Erk1/2-Nrf2/Bach1 signal pathway. Brain Res Bull 2017;130:236–44.

120. Kim JY, Paton JC, Briles DE, et al. Streptococcus pneumoniae induces pyroptosis through the regulation of autophagy in murine microglia. Oncotarget 2015;6:44161–78.

121. Vorobjeva NV, Chernyak BV. NETosis: molecular mechanisms, role in physiology and pathology. Biochemistry (Mosc) 2020;85:1178–90.

122. Fuchs TA, Abed U, Goosmann C, et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 2007;176:231–41.

123. Hakkim A, Fuchs TA, Martinez NE, et al. Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation. Nat Chem Biol 2011;7:75–7.

124. Amini P, Stojkov D, Felser A, et al. Neutrophil extracellular trap formation requires OPA1-dependent glycolytic ATP production. Nat Commun 2018;9:2958.

125. Papayannopoulos V, Metzler KD, Hakkim A, et al. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 2010;191:677–91.

126. Sollberger G, Choidas A, Burn GL, et al. Gasdermin D plays a vital role in the generation of neutrophil extracellular traps. Sci Immunol 2018;3:eaar6689.

127. Stojkov D, Amini P, Oberson K, et al. ROS and glutathionylation balance cytoskeletal dynamics in neutrophil extracellular trap formation. J Cell Biol 2017;216:4073–90.

128. Douda DN, Khan MA, Grasemann H, et al. SK3 channel and mitochondrial ROS mediate NADPH oxidase-independent NETosis induced by calcium influx. Proc Natl Acad Sci U S A 2015;112:2817–22.

129. de Bont CM, Boelens WC, Pruijn GJM. NETosis, complement, and coagulation: a triangular relationship. Cell Mol Immunol 2019;16:19–27.

130. Pham K, Parikh K, Heinrich EC. Hypoxia and Inflammation: Insights From High-Altitude Physiology. Front Physiol 2021;12:676782.

131. Yap YW, Whiteman M, Cheung NS. Chlorinative stress: an under appreciated mediator of neurodegeneration? Cell Signal 2007;19:219–28.

132. Kubota K, Saiwai H, Kumamaru H, et al. Myeloperoxidase exacerbates secondary injury by generating highly reactive oxygen species and mediating neutrophil recruitment in experimental spinal cord injury. Spine (Phila Pa 1976) 2012;37:1363–9.

133. Sun L, Li M, Ma X, et al. Inhibition of HMGB1 reduces rat spinal cord astrocytic swelling and AQP4 expression after oxygen-glucose deprivation and reoxygenation via TLR4 and NF-κB signaling in an IL-6-dependent manner. J Neuroinflammation 2017;14:231.

134. Kim SW, Lee JK. Role of HMGB1 in the interplay between NETosis and thrombosis in ischemic stroke: a review. Cells 2020;9:1794.

135. Neirinckx V, Coste C, Franzen R, et al. Neutrophil contribution to spinal cord injury and repair. J Neuroinflammation 2014;11:150.

136. Sun L, Wang H, Wang Z, et al. Mixed lineage kinase domain-like protein mediates necrosis signaling downstream of RIP3 kinase. Cell 2012;148:213–27.

137. Hitomi J, Christofferson DE, Ng A, et al. Identification of a molecular signaling network that regulates a cellular necrotic cell death pathway. Cell 2008;135:1311–23.

138. Choi ME, Price DR, Ryter SW, et al. Necroptosis: a crucial pathogenic mediator of human disease. JCI Insight 2019;4:e128834.

139. Andera L. Signaling activated by the death receptors of the TNFR family. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2009;153:173–80.

140. Holler N, Zaru R, Micheau O, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000;1:489–95.

141. Wang Y, Wang H, Tao Y, et al. Necroptosis inhibitor necrostatin-1 promotes cell protection and physiological function in traumatic spinal cord injury. Neuroscience 2014;266:91–101.

142. Fan H, Tang HB, Kang J, et al. Involvement of endoplasmic reticulum stress in the necroptosis of microglia/macrophages after spinal cord injury. Neuroscience 2015;311:362–73.

143. Fan H, Zhang K, Shan L, et al. Reactive astrocytes undergo M1 microglia/macrohpages-induced necroptosis in spinal cord injury. Mol Neurodegener 2016;11:14.

144. Shao L, Liu X, Zhu S, et al. The role of Smurf1 in neuronal necroptosis after lipopolysaccharide-induced neuroinflammation. Cell Mol Neurobiol 2018;38:809–16.

145. Liu M, Wu W, Li H, et al. Necroptosis, a novel type of programmed cell death, contributes to early neural cells damage after spinal cord injury in adult mice. J Spinal Cord Med 2015;38:745–53.

146. Fourquet S, Guerois R, Biard D, et al. Activation of NRF2 by nitrosative agents and H2O2 involves KEAP1 disulfide formation. J Biol Chem 2010;285:8463–71.

147. Wang Z, Jiang H, Chen S, et al. The mitochondrial phosphatase PGAM5 functions at the convergence point of multiple necrotic death pathways. Cell 2012;148:228–43.

148. Jia Z, Zhu H, Li J, et al. Oxidative stress in spinal cord injury and antioxidant-based intervention. Spinal Cord 2012;50:264–74.

149. Sims NR, Muyderman H. Mitochondria, oxidative metabolism and cell death in stroke. Biochim Biophys Acta 2010;1802:80–91.

150. Liu J, Kuang F, Kang R, et al. Alkaliptosis: a new weapon for cancer therapy. Cancer Gene Ther 2020;27:267–9.

151. Tang D, Kang R, Berghe TV, et al. The molecular machinery of regulated cell death. Cell Res 2019;29:347–64.

152. Hayden MS, Ghosh S. NF-κB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev 2012;26:203–34.

153. Furlong IJ, Ascaso R, Lopez Rivas A, et al. Intracellular acidification induces apoptosis by stimulating ICE-like protease activity. J Cell Sci 1997;110(Pt 5):653–61.

154. Jalalvand E, Robertson B, Tostivint H, et al. The spinal cord has an intrinsic system for the control of pH. Curr Biol 2016;26:1346–51.

155. Zhu S, Liu J, Kang R, et al. Targeting NF-κB-dependent alkaliptosis for the treatment of venetoclax-resistant acute myeloid leukemia cells. Biochem Biophys Res Commun 2021;562:55–61.

156. Jamison JM, Gilloteaux J, Taper HS, et al. Autoschizis: a novel cell death. Biochem Pharmacol 2002;63:1773–83.

157. Vanden Berghe T, Hassannia B, Vandenabeele P. An outline of necrosome triggers. Cell Mol Life Sci 2016;73:2137–52.

158. Weerasinghe P, Buja LM. Oncosis: an important non-apoptotic mode of cell death. Exp Mol Pathol 2012;93:302–8.

159. Gudz TI, Komuro H, Macklin WB. Glutamate stimulates oligodendrocyte progenitor migration mediated via an alphav integrin/myelin proteolipid protein complex. J Neurosci 2006;26:2458–66.

160. Alizadeh A, Dyck SM, Karimi-Abdolrezaee S. Myelin damage and repair in pathologic CNS: challenges and prospects. Front Mol Neurosci 2015;8:35.

161. Syntichaki P, Tavernarakis N. Death by necrosis. Uncontrollable catastrophe, or is there order behind the chaos? EMBO Rep 2002;3:604–9.

162. Martin LJ. Neuronal cell death in nervous system development, disease, and injury (Review). Int J Mol Med 2001;7:455–78.

163. Beattie MS, Hermann GE, Rogers RC, et al. Cell death in models of spinal cord injury. Prog Brain Res 2002;137:37–47.

164. Simard JM, Tsymbalyuk O, Ivanov A, et al. Endothelial sulfonylurea receptor 1-regulated NC Ca-ATP channels mediate progressive hemorrhagic necrosis following spinal cord injury. J Clin Invest 2007;117:2105–13.

165. Brewer KL, Nolan TA. Spinal and supraspinal changes in tumor necrosis factor-alpha expression following excitotoxic spinal cord injury. J Mol Neurosci 2007;31:13–21.

166. Chen KB, Uchida K, Nakajima H, et al. Tumor necrosis factor-α antagonist reduces apoptosis of neurons and oligodendroglia in rat spinal cord injury. Spine (Phila Pa 1976) 2011;36:1350–8.

167. Martin LJ, Al-Abdulla NA, Brambrink AM, et al. Neurodegeneration in excitotoxicity, global cerebral ischemia, and target deprivation: a perspective on the contributions of apoptosis and necrosis. Brain Res Bull 1998;46:281–309.

168. Tator CH. Update on the pathophysiology and pathology of acute spinal cord injury. Brain Pathol 1995;5:407–13.

Article information Continued

This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Classification	Mode of cell death	Relation to pathogenesis in SCI	Treatment method targeting pathways	References
Programmed apoptotic cell death	Extrinsic apoptosis Intrinsic apoptosis	1. Death of astrocytes, neurons, mi- croglia, and oligodendroglia	1. XIST KO to reduce neuronal death.	[36,38,39,43]
			2. Targeting CARD6 to block Caspase-3
		2. Promote Wallerian degeneration	3. Minocycline to block CD95 [Fas] ligand
			4. Glycol to block sphingolipid-induced iNOS
			5. Metformin to increase β-catenin and BDNF expression
	Anoikis	1. Impairment of ECM remodeling	1. Use of MSCs	[46,47]
	Anoikis	2. Promote myelin degeneration	2. Use of BDNFs	[46,47]
Programmed nonapoptotic cell death	Autophagy	1. Stabilization of microtubules by degradation of SCG10	1. Metformin to increase autophagy in SCI cells	[57,58,65]
		2. increase in axon development	2. SCG10 to promote microtubule stabiliza- tion and axon recovery
		3. Protection of neurons from ER stress	3. ABT888 to suppress autophagy
	Paraptosis	1. Increase in p44 expression in the CNS to promote neuronal death	Not discovered yet	[73]
	Mitoptosis	1. Cell death in penumbra and lesion after SCI by elevation of Bax: Bcl-2 ratio	Being researched	[85]
	Parthanatos	1. Kainite excitotoxicity	1. 6-5[H]-phenanthridine to prevent AIF translocation and overactivation of PARP-1	[96,97]
	Parthanatos	2. Oxidative stress	2. PJ34 to reduce kainite excitotoxicity	[96,97]
	Ferroptosis	1. Excitotoxicity-induced cell death	1. Deferoxamine to lower Fe²⁺ levels	[105]
	Ferroptosis	1. Excitotoxicity-induced cell death	2. Proanthocyanidins to suppress ferroptosis and promote functional recovery	[105]
	Netosis	1. Promoting Secondary injury by HOCl formation.	Being researched	[123,131]
		2. Producing NETs to worsen the injury
		3. Cell swelling by HMGB1 induced AQP4 activation
	Pyroptosis	1. Neuronal death by GSDMD cleavage by caspase 1	Being researched	[110]
	Necroptosis	1. TNFR-induced cell death	1. PSMB4 by regulating RIP3^w and MLKLpathways	[83]
	Necroptosis	1. TNFR-induced cell death	2. NEC-1 by recruiting RIP1/3–MLKL	[83]
Nonprogrammed nonapoptotic cell death	Nonprogrammed necrosis	1. Neurological impairment	Being researched	[162,164]
		2. spinal cord tissue loss
		3. Cystic cavitation of the spinal cord
		4. NMDA excitotoxicity